Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT ID: NCT01266265

Last Updated: 2016-02-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1333 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A post marketing surveillance to determine the type and incidence of oro/nasopharyngeal or pulmonary adverse events that may occur in patients treated with commercially available Tyvaso®(treprostinil) Inhalation Solution. A comparison will be made to the type and incidence of events in patients receiving other FDA approved therapies for pulmonary arterial hypertension, as a control measure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tyvaso

The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.

inhaled prostacyclin

Intervention Type DRUG

Tyvaso

Control

The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.

inhaled prostacyclin

Intervention Type DRUG

As prescribed by the physician

prostacyclin

Intervention Type DRUG

As prescribed by the physician

subcutaneous and intravenous prostacyclin

Intervention Type DRUG

As prescribed by physician

oral ERA

Intervention Type DRUG

As prescribed by physician

oral PDE5 inhibitors

Intervention Type DRUG

As prescribed by physician

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

inhaled prostacyclin

Tyvaso

Intervention Type DRUG

inhaled prostacyclin

As prescribed by the physician

Intervention Type DRUG

prostacyclin

As prescribed by the physician

Intervention Type DRUG

subcutaneous and intravenous prostacyclin

As prescribed by physician

Intervention Type DRUG

oral ERA

As prescribed by physician

Intervention Type DRUG

oral PDE5 inhibitors

As prescribed by physician

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

treprostinil iloprost, Ventavis epoprostenol sodium, Flolan treprostinil , Remodulin bosentan, Tracleer ambrisentan, Letairis sildenafil, Revatio tadalafil, Adcirca

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of PAH, WHO GROUP I
* Prescribed and is currently receiving Tyvaso and/or other FDA-approved therapy for the treatment of PAH
* Willing and able to provide written informed consent

Exclusion Criteria

* Previous initiation and permanent discontinuation of Tyvaso
* Participation in an investigational clinical drug or device trial within 30 days of enrollment
* Current or past diagnosis of lung neoplasm
* Active gastrointestinal or pulmonary bleed at enrollment
* Planned surgical intervention for treatment of PAH e.g., atrial septostomy or transplant
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiovascular Associates, P.C.

Birmingham, Alabama, United States

Site Status

The University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

University of South Alabama

Mobile, Alabama, United States

Site Status

Arizona Pulmonary Specialists, LTD

Phoenix, Arizona, United States

Site Status

Berkeley Cardiovascular Medical Group

Berkeley, California, United States

Site Status

Cedars-Sinai Heart Institute

Beverly Hills, California, United States

Site Status

University California San Francisco

Fresno, California, United States

Site Status

University of Southern California

Los Angeles, California, United States

Site Status

West Los Angeles VA Healthcare Center

Los Angeles, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

University of California, San Francisco

San Francisco, California, United States

Site Status

Paloma Medical Group

San Juan Capistrano, California, United States

Site Status

Santa Barbara Cottage Hospital

Santa Barbara, California, United States

Site Status

Stanford Hospital and Clinics

Stanford, California, United States

Site Status

Children's Hospital Denver

Denver, Colorado, United States

Site Status

Western States Clinical Research, Inc.

Wheat Ridge, Colorado, United States

Site Status

St. Francis Sleep Allergy & Lung

Clearwater, Florida, United States

Site Status

University of Florida

Gainesville, Florida, United States

Site Status

Pulmonary and Critical Care Associates

Jacksonville, Florida, United States

Site Status

University of Florida College of Medicine Jacksonville

Jacksonville, Florida, United States

Site Status

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Site Status

Miami Center for Cardiovascular Disease

Miami, Florida, United States

Site Status

Mount Sinai Medical Center

Miami Beach, Florida, United States

Site Status

Central Florida Pulmonary Group, P.A.

Orlando, Florida, United States

Site Status

Orlando Heart Center

Orlando, Florida, United States

Site Status

Cleveland Clinic Florida

Weston, Florida, United States

Site Status

Emory University School of Medicine

Atlanta, Georgia, United States

Site Status

Georgia Lung Associates, PC

Austell, Georgia, United States

Site Status

Northwestern Medical Center

Chicago, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

Midwest Heart Foundation

Oakbrook Terrace, Illinois, United States

Site Status

Indiana University Hospital

Carmel, Indiana, United States

Site Status

University of Iowa

Iowa City, Iowa, United States

Site Status

Mercy Hospital

Iowa City, Iowa, United States

Site Status

University of Kansas Medical Center

Kansas City, Kansas, United States

Site Status

Kentuckiana Pulmonary Associates

Louisville, Kentucky, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

Tufts - New England Medical Center

Boston, Massachusetts, United States

Site Status

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Henry Ford Health System

Detroit, Michigan, United States

Site Status

William Beaumont Hospital

Troy, Michigan, United States

Site Status

Mayo Clinic

Rochester, Minnesota, United States

Site Status

Nebraska Pulmonary Specialties, LLC

Lincoln, Nebraska, United States

Site Status

Hackensack University Medical Center

Hackensack, New Jersey, United States

Site Status

UMDNJ - Robert Wood Johnson Medical Center Clinical Research Center

New Brunswick, New Jersey, United States

Site Status

Newark Beth Israel Medical Center

Newark, New Jersey, United States

Site Status

SUNY Stony Brook University Medical Center

Islandia, New York, United States

Site Status

Winthrop Pulmonary Associates

Mineola, New York, United States

Site Status

North Shore - Long Island Jewish Health System

New Hyde Park, New York, United States

Site Status

St. Luke's-Roosevelt Hospital Center

New York, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Mary M Parkes Center

Rochester, New York, United States

Site Status

Pulmonary Health Physicians

Syracuse, New York, United States

Site Status

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Site Status

Pinehurst Medical Clinic

Pinehurst, North Carolina, United States

Site Status

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Akron General Hospital

Akron, Ohio, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

University Hospitals of Cleveland

Cleveland, Ohio, United States

Site Status

Davis Heart and Lung Research Institute

Columbus, Ohio, United States

Site Status

Mercy Fairfield Hospital

Fairfield, Ohio, United States

Site Status

Legacy Pulmonary Northwest

Portland, Oregon, United States

Site Status

Oregon Clinic, PC

Portland, Oregon, United States

Site Status

OHSU-Oregon Health and Science University

Portland, Oregon, United States

Site Status

Penn State Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

University of Pennsylvania Health System

Philadelphia, Pennsylvania, United States

Site Status

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Site Status

Temple University

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Berks Schuylkill Respiratory Specialists, Ltd.

Wyomissing, Pennsylvania, United States

Site Status

Rhode Island Hospital

Providence, Rhode Island, United States

Site Status

Lexington Pulmonary and Critical Care

Lexington, South Carolina, United States

Site Status

MD Total Care, PLLC

Chattanooga, Tennessee, United States

Site Status

Summit Medical Group

Knoxville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

Baylor College of Medicine

Houston, Texas, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

University of Texas Health Science Center at Houston

Houston, Texas, United States

Site Status

Methodist Healthcare System of San Antonio

San Antonio, Texas, United States

Site Status

University of Texas Health Science Center at San Antonio

San Antonio, Texas, United States

Site Status

Inova Fairfax Hospital

Falls Church, Virginia, United States

Site Status

Sentara Cardiovascular Research Institute

Norfolk, Virginia, United States

Site Status

Aurora Health Care

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Zamanian RT, Levine DJ, Bourge RC, De Souza SA, Rosenzweig EB, Alnuaimat H, Burger C, Mathai SC, Leedom N, DeAngelis K, Lim A, De Marco T. An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension. Pulm Circ. 2016 Sep;6(3):329-37. doi: 10.1086/688059.

Reference Type DERIVED
PMID: 27683610 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RIN-PH-403

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.